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ABSTRACT 
 
The purpose of this study is to develop a unique nanoparticulated system that has the 
capability of providing sustained drug delivery into the eyes. In ophthalmic preparations, poor 
ocular drug delivery of ocular dosage form is due to the production of tears and impermeability 
through corneal epithelium. The usage of liposomes in ophthalmic disorders shows promising 
results in ocular drug delivery. Liposomes are bilayered, microscopic vesicles surrounded by the 
aqueous compartments. Liposomes have the ability to encapsulate both hydrophilic and 
hydrophobic drugs. This unique property of liposomes helps in delivering the drug at specific 
site. This invention involves three major components: first, encapsulating of both hydrophilic 
and hydrophobic drugs into the liposomes. Second, incorporate liposomes into polymeric coating 
material with a volatile carrier solvent. Finally, apply liposome incorporated coating composite 
into intraocular lenses. When volatile solvent evaporates, the coated polymer with liposomes will 
form a thin film upon the intraocular lens. Local application of encapsulated coated intraocular 
lenses helps in the successful controlled, sustained time release of the drug in to the target site 
helps in prevention and treatment of ophthalmic diseases. 
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INTRODUCTION 
 
The eye is a unique and precious organ in human body, characterized by its complex 
structure and impermeable to foreign substances including drugs. The drug delivery to the 
specified targeted region of eye is difficult because of the specialized anatomical and 
physiological nature of the eye. The physiological and anatomical barriers allow only a small 
fraction of the drug, usually 1-5% of the instilled dose to be effectively absorbed. The two major 
constraints that result in relatively poor ocular bioavailability are the pre corneal loss factions 
and the relative impermeability of the corneal epithelium membrane. [1]  
 The structure of eye can be explained under two segments i.e. anterior segment and 
posterior segment. Anterior segment consists of front part of the eye which includes pupil, 
cornea, iris, ciliary body, aqueous humor and lens where as posterior segment includes two third 
of eye, includes vitreous humor, retina, choroid, macula and optic nerves. [18] 
 
Fig1: The Anatomy of the Eye [15] 
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 Millions of people suffer from a wide variety of ocular diseases, many of which lead to 
visual impairment and ocular blindness. Certain ocular diseases like Cataracts, Age related 
Macula and Glaucoma are very common in aging people. 
Macular degeneration is the leading cause of severe vision loss in many people over age 
60. As the disease develops with person ages, it is often referred to as age-related macular 
degeneration (AMD). Age-related Macular Degeneration is a chronic, degenerative disease of 
the macula, the central portion of the retina that results primarily in central vision loss whereas 
the peripheral vision remains unaffected. It occurs when the small central portion of the retina, 
known as the macula, deteriorates. It is the third major cause of adult blindness worldwide, and 
the first in industrialized countries [2]. 
 
Fig2: Macular Degeneration [15] 
 
There are two main types of age-related macular degeneration: 
Dry AMD: 
The "dry" form of macular degeneration is characterized by the presence of yellow 
deposits, called “drusen” in the macula. As the drusen grow in size and increase in number, they 
may lead to a dimming of vision. In more advanced stages of dry macular degeneration, there is 
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also a thinning of the light-sensitive layer of cells in the macula leading to atrophy, or tissue 
death. In the atrophic form of dry macular degeneration, patients may have blind spots in the 
center of their vision. [8]  
Wet AMD:  
The "wet" form of macular degeneration is characterized by the growth of abnormal 
blood vessels from the choroid underneath the macula. It is called choroidal neovascularization. 
These blood vessels leak blood and fluid into the retina, causing distortion of vision that makes 
straight lines look wavy, as well as blind spots and loss of central vision. These abnormal blood 
vessels eventually scar, leading to permanent loss of central vision. [8]  
Wet macular degeneration further falls into two categories: 
 Occult: Vision loss is not as severe as compared to the classic form because of 
comparatively less new blood vessel growth beneath the retina and the consequent 
leakage. 
 Classic: Usually produces more severe vision loss where new blood vessel growth and 
scarring beneath the retina is more severe. [2] 
 Other major causes of blindness in older individuals include: Presbyopia, Cataract, 
Glaucoma and Diabetic Retinopathy.  
Presbyopia is a condition where there is a difficulty to see the objects close by, because 
the eye lens loses its ability to focus. These age-related changes occur within the proteins in the 
lens, making the lens harder and less elastic over time.  
Fig3: Presbyopia of the Eye [15] 
 
Nanoparticulated Ocular Drug Delivery Page 7 
 
Glaucoma is an eye condition that develops when too much fluid pressure builds up 
inside the eye. The increased pressure, called intraocular pressure, can damage the optic nerve, 
which transmits packets of images to the brain. If damage to the optic nerve from high eye 
pressure continues, glaucoma will cause loss of vision. Without treatment, glaucoma can cause 
total permanent blindness within a few years. 
 
Fig4: Glaucoma [15] 
 
 
 
Diabetic Retinopathy is caused by damage to the fragile blood vessels of the retina. In 
Diabetic Retinopathy blood vessels may swell and leaks fluids. It could further develop cataracts 
and glaucoma. It results in changes in veins, arteries and capillaries in the body. 
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Fig5: Diabetic Retinopathy [15] 
 
 
 
Cataracts are changes in clarity of the natural lens inside the eye by the accumulation of 
turbulent fluid, which gradually degrade visual quality. Cataract surgery is very successful 
treatment for the restoration of vision. During surgery, the clouded lens i.e. turbulent fluid is 
removed and replaced it with a clear, intra ocular lens. In Cataract Surgery, by using an operating 
microscope, a small incision, usually around 3 millimeters long, is made in the eye. Precise 
surgical instruments are used to break apart and remove the cloudy lens from the eye. In most 
cases, the natural lens is then replaced with a permanent intraocular lens (IOL) implant. This IOL 
is clear and is intended to stay in the eye forever. The incision typically does not require stitches. 
This small incision, no-stitch technique, has drastically reduced the recovery time for modern 
cataract surgery. [6], [7] 
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Fig6: Cataracts [15] 
 
 
Fig 7: Cataract Surgery [15] 
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Cataract surgery can increase the risk of retinal detachment slightly. Other complications 
after the surgery include infection, bleeding, inflammation, loss of vision, double vision, and 
high or low eye pressure. Intraocular drug delivery is the best mode to achieve highest 
intraocular bioavailability in the posterior segment tissues such as the macula or fovea. This is 
possible because it is the only drug delivery which directly circumvents the Blood Retinal 
Barrier (BRB) and thus highest peak Intravitreal or intraretinal drug concentrations are attained. 
So far, the main treatment strategy for the diseases of the posterior segment mainly, the Age 
Related Macular Degeneration is the intravitreal injection, which involves direct injection of the 
drugs into the vitreous humor. The advantages of this treatment option are that it directly 
broaches BRB and high drug levels in the retina are achieved. But the main problem is that good 
patient compliance isn’t achieved as this is a very painful technique. Besides, there are several 
other complications such as increased intraocular pressure, floaters, vitreous hemorrhage, 
transient blurry vision, retinal tears, retinal detachment, development of endophthalmitis, 
glaucoma and cataract.  Endophthalmitis is the inflammatory condition of the intraocular cavities 
i.e. the aqueous and vitreous humor usually caused by infection. [1] 
 
Fig 8: Intravitreal Injection [15] 
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Thus there is a need to develop a simple, non-invasive technique which besides 
improving the ocular bioavailability and therapeutic efficacy achieves better patient compliance 
and overcomes the problems encountered with the previous techniques. 
Intra Ocular Lens (IOL): 
In the past, people had to use very thick eye glasses or special contact lenses to be able to 
see after cataract surgery. Now, several types of IOL implant are available to help people to 
improve their vision. IOL  is the artificial lens implanted during the Cataract surgery, to replace 
the natural lens of eye, as it becomes cloudy. Basically natural lens of eye is made up of proteins, 
the linkage formed between the proteins leads to the formation of the cloudy, turbulent fluid in 
the eye and this causes the blurred vision of the eye. Intraocular lens works as natural lens of eye. 
They basically provide a clear, optical path and also restorative refractive capability to the eye [3].  
IOLs are made of either hard plastic or soft, foldable polymers such as PMMA, 
hydrophilic acrylics, poly (2-hydroxyethyl methacrylate) or silicone. In 1981 for the First time 
FDA approved IOL. [9] The basic function of IOL is to focus the light onto the retina, where the 
packets of images are converted into electrical impulses that travel to the brain. The basic 
construction of IOL is shown at the following figure.   
 
Fig 9: Intraocular Lens [17] 
 
 
 
The round, corrective central portion acts as the refractive element with two arms which 
provide structural support for the lens in the lens capsule of the eye [4]. The center viewing zone 
is called the optic. This is a clear, round disc measuring 5.5 to 6.5 mm in diameter. On opposite 
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side of the optic, there are two flexible struts are present, which are called as Haptics. These 
Haptics acts like tension loaded springs to automatically center the lens within the compartment. 
There are different types of IOL’s are used in cataract surgery. Mainly three types of 
IOL’s are used in cataract surgery. They are 
 Monofocal lens 
 Multifocal lens 
 Toric lens 
Monofocal lenses are used for distance vision, by provides a single focal point. 
Multifocal IOL’s are advanced type of IOL’s used for multiple focal points and reduces the 
usage of eyeglasses or contact lenses after the cataract surgery. Toric lenses are the special type 
of lenses used to reduce the astigmatism of the eye at time of surgery. [9], [10] Examples include: 
Crystalens, AcrySof IQReSTOR from Alcon’s and Technis and ReZoom from Abott Medical 
Optics.  
IOLs are commercially available as:  
 Premium IOLs, 
 Toric IOLs,  
 Blue light-filtering IOLs, 
 Aspheric IOLs, 
 Piggyback IOLs. 
Fig 10: Types of Intraocular lens [17] 
 
 
The main advantage of using IOLs is that they allow us to study sustained release of 
therapeutic levels of drug for a desired period of time, thus overcoming Blood Retinal Barrier 
which is associated with systemic drug delivery. [4], [10] 
Nanoparticulated Ocular Drug Delivery Page 13 
 
Nanoparticles: 
Nanoparticles are submicron sized colloidal particles with lengths in 2 or 3 dimensions 
greater than 1nm and smaller than 100nm. This sub-class of ultra-fine particles may or may not 
exhibit a size-related intensive property. The small size of the nanoparticles allows them to 
efficiently penetrate across the biological barriers through small capillaries all over the body. 
This allows nanoparticles, to access into various cells and cellular compartments including the 
nucleus, thus allowing efficient drug accumulation at the actual targeted site. The unwanted side 
effects and the toxicity of the drug are thus reduced while enhancing the therapeutic efficiency[5]. 
There are several other advantages of using nanoparticles as drug delivery systems: 
 Solubility of the drug is increased, can be used for all routes of administration. 
 Protects the drug from degradation i.e. protect the drug from chemical or 
enzymatic hydrolysis 
 Can be formulated easily and rapidly.  
 Sustained drug release and prolonged therapeutic activity 
 Novel drug delivery tool for chronic ocular diseases 
 Site-specific targeting -surface modification with ligands 
 P-glycoprotein circumvention –higher cellular permeability 
 Efficient in crossing membrane barriers -blood retinal barrier 
 Act as an inert carrier for ophthalmic drugs 
 More stable than colloidal system 
 Time release studies 
In ocular drug delivery, an important consideration would be to obtain therapeutic 
concentrations within the retina by increasing the relative permeability of the Blood Retinal 
Barrier(BRB). Use of nanoparticles is an effective strategy to enhance the BRB transport. There 
are various methods for loading the drugs onto nanoparticles such as encapsulation, surface 
attachment or entrapment.  
In this research, encapsulation is the method followed for loading the drug. As 
nanoparticles are colloidal systems, the stability of these formulations is very important. This can 
be improved by the use of polymeric surfactants, or other modifiers. The surfactants are adsorbed 
or grafted to the particles and form a layer, which produces repulsive force between the 
nanoparticles and prevent flocculation [5]. 
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It has been shown that the drug delivery using nanoparticles can enhance the 
bioavailability of drug in target site. In the current research we develop a unique nanoparticle 
system i.e. liposomes as an ocular drug delivery. Liposomes are microscopic vesicles composed 
of lipid bilayered membrane surrounded by aqueous compartments. The lipid bilayered 
membrane mostly composed of phospholipids. These phospholipids are amphiphlic, having 
hydrophilic head and hydrophobic/lipophilic tail. In the bilayered membrane these nonpolar tails 
located in interior of the membrane and polar heads are pointing towards the outside of 
membrane. This property helps in encapsulation of both hydrophilic and lipophilic drugs in 
liposomes. [11] These liposomes are classified into various types based on their size i.e. 
unilamellar vesicles (ULV) and multilamellar vesicles (MLV). These unilamellar vesicles again 
divided into small unilamellar vesicles (SUV) and large unilamellar vesicles (LUV). These large 
size vesicles can be modified into small vesicles by using sonicator. [12] 
Fig 11: Nanoparticle Structure [16] 
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In the current study we used time release technology which is Sustained Release (SR) 
Technology. The advantages of this time-release technology are uniform release of drug 
substance over time, reduction in the frequency of drug administration, reduced side effects, and 
better patient compliance. Sustained release is the slow release of the drug over a time period. In 
this, the drug concentration will vary with time interval because the initial release of the drug is 
sufficient to provide a therapeutic dose soon after the administration and then gradual release of 
the drug takes place over an extended time period. 
 
EXPERIMENTAL METHODS 
Fluorescein Sodium Salt from Sigma Chemical Company is used as a biomarker. It is a 
hydrophilic fluorophore with anhydrous molecular weight of 376.3gm and has an absorption 
maximum at 494nm and emission maximum at 521nm.  It is an orange-red powdered compound 
that exhibits intense greenish-yellow fluorescence. Major applications of Fluorescein include 
Nanolithography, nanoparticles, and thin films. It is used in various areas of ophthalmology, 
especially in retinal vasculature imaging (diagnosis of Diabetic Retinopathy) to reveal corneal 
lesions and as a systemic biomarker in numerous pharmacokinetic studies. The Flurometer used 
is Ocean Optics 2000+.from Ocean Optics. The Sonicator used in this study is UP100H from 
Hielscher ultrasound technology. 
Nanoemulsions are dispersions of fine droplets (in nanometer range) in a dispersion 
medium. So they are thermodynamically unstable. Thus they require considerable mechanical 
energy during their preparation to enhance the stability. Choosing the oil phase and the 
surfactants are important consideration in the formulation of nanoemulsions, so as to be able to 
carry both polar and non-polar drugs and improve control over the release of therapeutic 
molecules. Most widely used oils are various fixed oils of vegetable origin. Oils used: Castor oil, 
a hydrophilic non-ionic surfactant is the oil used. Other vegetable oils such as olive oil, canola 
oil and almond oil are also used.  
 
 
 
 
Nanoparticulated Ocular Drug Delivery Page 16 
 
Surfactants: 
Surfynol-465 has a great solubility in water. All the Surfynol 400 Series surfactants have 
a unique combination of formulating benefits like greater dispersion, emulsification, wetting etc.  
Polaxomer 407 is a hydrophilic, non-ionic copolymer, mostly used in cosmetics. This 
surfactant also used in contact lens cleaning solution. It is non toxic so it is widely used in oral 
and topical pharmaceutical products. 
 PEG 3350 is an excipient used as an emulsifier, binder and surfactant. It improves 
resistance to moisture and oxidation. Polyethylene is a polymerized ethylene resin and glycol is a 
hydric alcohol. It is highly soluble in water, so it can couple to hydrophobic molecules. 
 Asolectin is a mixture of phospholipids. It is made from soybean and mainly used as oil 
in water emulsifier. It is used to reconstitute acetylcholine receptor into liposomes. Asolectin 
comprises roughly equal proportions of lecithin, cephalin and phosphatidylinositol along with 
minor amounts of other phospholipids and polar lipids.  
 
Drugs Used: 
Two pharmacological classes of drugs have been used: 
 Antibiotics – Vancomycin 
It is a glycopeptides antibiotic. Anti-bacterial mostly used to treat colitis. 
Anti-inflammatory – Alclofenac 
It is a Non-steroidal Anti-inflammatory drug, analgesic and anti-pyretic. 
 
Coating: 
Coating is an important part of the sustained release forms. 
Purpose of coating; 
 Obtain functional coats. 
 Provide chemical stability. 
 Enhance patient acceptance 
 
Properties of the coating material for IOL coating: 
 Biodegradable, 
 Highly flexible polymeric coating with sustained release effect,  
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 Easy applicability, 
 Fast drying or curing, 
 Excellent adhesion to IOL, 
 Low solvent emission and should be safe in workplace, 
 Should leave no residue after removal from the applied surface. 
 
Materials used for the preparation of the coating formulation: 
Polycaprolactone is the polymer used. It is a biodegradable, synthetic thermoplastic 
polymer used in a number of biomedical applications. It is hydrophobic and slow-degrading. It is 
most commonly used in controlled drug delivery systems and in implants. [14] 
Collodion Solution from Fluke Analytical, Contains: Nitrocellulose, Ethyl alcohol and 
Ether Solution. It is an excellent coating material and when the solvent is evaporated it leaves a 
tough, clear, transparent film. [14] 
Hydroxy Propyl Methyl Cellulose is a biodegradable, base celluloid compound that is 
highly water soluble. It is also called s hypromellose. Hypromellose 2% solution has been 
documented to be used during surgery to aid in corneal protection and during orbital surgery. It 
is a good coating material that forms a clear transparent film on IOL. It is available in different 
molecular weights. In this experiment we used three different molecular weights i.e. 10000, 
90000 and 120000. 
 
Materials for the preparation of PMMA implants: 
PMMA:  
Poly (methyl methacrylate) is a synthetic, transparent plastic, versatile biocompatible 
polymeric material for coating used in a number of medical applications. It has a high surface 
area and low density, which make it an excellent seeding and coating material for antibiotic 
encapsulated nanoparticles. [14] 
MMA: 
Methyl methacrylate is a synthetic chemical used in coating formulations. Advantages of 
biodegradable implants are they don’t have to be removed or absorbed or eliminated from the 
body. [14] 
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IOL: 
Intra ocular lenses supplied by AMO-Inc, Abbott Laboratories.USA 
 
EXPERIMENTAL PROCEDURE 
 For the preparation of nanoparticles, we need to prepare the stock solution of Fluorescein, 
and then we need to prepare the micelles followed by the preparation of liposomes. 
1M Fluorescein Stock Solution: 
 37.63 gm of Fluorescein Sodium Salt was taken and dissolved in a small amount of 
distilled water on a hot plate with continuous stirring. Then make up the volume to 100mL. 
Poloxamer 407 Solution: 
1gm of Poloxamer 407 + 30ml water under low heat with constant stirring 
PEG 3350 Solution: 
1gm of PEG 3350 + 30ml water under low heat with constant stirring. 
Preparation of PMMA implant: 
Formulation 1-A: 
18 g of Polymethylmethacrylate (PMMA) + 12 mL methyl methacrylate (MMA)  
Formulation 1-B: 
18 g of PMMA + 12 mL MMA + 5 mL EMA 
Thoroughly mix the above formulation separately in a glass beaker in a chemical hood 
with constant stirring. The mixture is then cast in a molding plate, made of Al or Sn with the 
desired thickness. The casting plate is then kept in the oven for over 2 hours at 800C in order for 
the PMMA to cure. [14] 
 
Inverted micelle (W/O Nanoemulsion): 
Formulation 2–A: 
 10mL of castor oil is taken and heated gently on a low heat. 
 2mL of Surfynol-465 is added to the above oil and dissolved on a low heat with constant 
stirring with a magnetic bead, until it forms a homogeneous mixture. 
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 Aqueous phase i.e. fluorescein is added drop wise to the above mixture, maintaining low 
heat and continuous stirring until a viscous, homogeneous water-in-oil emulsion is 
obtained. Approximately 30 drops i.e. 1.5 ml could be incorporated into the mixture.  
 The emulsion is then kept for overnight stirring to obtain a clearer, homogeneous 
emulsion. 
Formulation 2-B: 
 10mL of castor oil is taken and heated gently on a low heat. 
 0.1 gm of Asolectin is added to the above oil and dissolved on a low heat with constant 
stirring until it forms a homogeneous mixture. 
 Aqueous phase i.e. fluorescein with 2ml of poloxamer 407 is added drop wise to the 
above mixture, maintaining low heat and continuous stirring until a viscous, 
homogeneous emulsion is obtained. Approximately 12 drops added to the mixture.  
 The emulsion is then kept for overnight stirring to obtain a clearer, homogeneous 
emulsion. 
 
Liposomes (O/W/O Nanoemulsions): 
Formulation 3-A: 
 10 ml of Poloxamer solution is taken and heated gently under low heat. 
 To the above solution inverted micelle i.e. W/O emulsion is added drop wise with 
continuous stirring under low heat until it forms a homogeneous and clear solution. 
 Approximately 18 drops of inverted micelle incorporated in the above solution. 
Formulation 3-B: 
 10 ml of PEG 3350 solution is taken and heated gently under low heat. 
 To the above solution inverted micelle i.e. W/O emulsion is added drop wise with 
continuous stirring under low heat until it forms a homogeneous and clear solution. 
 Approximately 14 drops of inverted micelle incorporated in the above solution. 
 Sonicate for 15 min.  
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Coating of Nanoemulsions: 
 These prepared nanoemulsions are incorporated into a polymeric coating material to 
study sustained release properties. 
 The coating solvent should be non-toxic and it should be easily evaporated once it is 
coated on to the IOL surface. 
 The coating material must be easily dried, so the coating material must prepare just 
before 10 min, before the coating is done. 
 Nano particles were mixed with carrying solvent and a binding agent to prepare slurry 
which has good binding capacity. 
Coating Formulation: 
 Dissolve 0.2 g of Polycaprolactone in 2.0 mL of nitrocellulose and 2.0 mL of acetone 
with constant stirring under very low heat.  
 Add acetone drop by drop in the beaker until the polymer is totally dissolved. 
 About 1mL of MMA is added to this to improve the adhesive nature of the coating 
formulation. 
 To the above formulation, Liposome (w/o/w Nanoemulsion) is added drop wise with the 
continuous addition of acetone.  
 Approximately 38 drops of liposome i.e. w/o/w emulsion is incorporated in coating 
formulation. 
 
Coating of PMMA implant: 
Approximately 2 mL of the coating formulation is taken and coated on the PMMA 
implant carefully with a paint brush.  The coated PMMA implant is then allowed to dry 
overnight. 
 
Coating of IOL: 
 Intra Ocular Lens is gently held with tweezers by holding one of the Haptics. 
 It is then dipped in the coated formulation gently to coat both the sides of the IOL.  
 IOL is then allowed to air-dry for 24 hours by covering it with an aluminium foil.  
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**Throughout the experimental procedure, all the glassware and the test tubes are covered with 
aluminium foil to prevent any photo activity of Fluorescein. 
 
Testing of IOL for Sustained Release Studies: 
 Simulated vitreous humor and aqueous humor are prepared for testing the sustained 
release of the drug from the coated IOL. 
 The coated IOLs are then placed in them. Samples are collected from the simulated 
vitreous humor on a daily basis (at 24 hour interval) and hourly basis and the 
fluorescence intensity is measured. 
RESULTS AND DISCUSSIONS 
 
Evidence for Encapsulation of Liposomes: 
 An evidence for encapsulation of drug in to nanoparticles is provided by the Fluorescence 
technique by which we can examine the nanoparticles. 
 
Fig 12: Evidence of Nanoparticle Formulation 
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The graph provides a good evidence for the encapsulation of the drug into the nanoparticles. 
Fluorescein dye in aqueous solution used as a bio-marker which gives an intensive peak ( blue) 
and some concentration of fluorescein dye solution trapped inside the formulation 3-A and 3-B 
liposomes ( red). Graph shows a decreased intensity of fluorescence of drug in water when 
compared to that of the drug in the liposomes which indicates that drug is encapsulated in to the 
liposomes. This is because of the multi lamellar structure of the liposomes. The shift in the graph 
which is blue shift shows an increase in the polarity of the drug and also represents the drug 
movement to more hydrophilic environment. 
 
Sustained Release Studies: 
Simulated vitreous humor and aqueous humor was prepared to examine the sustained 
release kinetics. A luminescence bio-marker was encapsulated inside the liposomes instead of 
the antibiotic drugs in order to monitor the sustained release. We used vancomycin to simulate 
the hydrophobic drug and fluorescence dye i.e. fluorescein to simulate the hydrophilic drug. The 
coated Intra ocular lens with encapsulated luminescence bio marker was submerged inside the 
vitreous humor or aqueous humor and the fluorescence was measured in a time interval of 1 hour 
for a period of 16hours. The intensity of fluorescence indicates the amount of drug that is 
released from the coating polymer into the vitreous humor and aqueous humor. Sustained release 
of fluorescein dye was observed up to 16 days. The liposome thus provides the initial release of 
drug.  
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Table 1: Fluorescence intensities taken on an hourly basis 
 
S.No Time(Min) 
Relative 
Fluorescence 
Intensity 
1 60 748.00 
2 120 935.00 
3 180 877.00 
4 240 954.01 
5 300 1031.00 
6 360 1040.29 
7 420 1123.44 
8 480 1245.40 
9 540 1293.00 
10 600 1388.01 
11 660 1483.01 
12 720 1620.90 
13 780 1823.21 
14 840 1848.68 
15 900 1869.68 
16 960 1989.40 
 
Fig 13: Hourly Drug Release 
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Table 1 shows the Fluorescence intensity studies taken on hourly basis i.e. for every 
1hour. We took the fluorescence intensity of the drug measured for a time period of 16 hours. A 
Graph was plotted on the hourly basis of drug release. This shows the increase in intensity of 
fluorescence from first hour to sixteenth hour. The Fluorescence intensity increased from 748.00 
(1st hour) to 1989.40 (16th hour).  
 
Table 2: Fluorescence intensities taken on daily basis 
 
S.No Time( Hr) Relative Fluorescence Intensity 
1 24 8107.21 
2 48 16550.82 
3 72 20032.86 
4 96 26157.76 
5 120 44001.84 
6 144 63652.72 
7 168 66919.12 
8 192 70573.76 
9 216 80996.00 
10 240 83583.28 
11 264 129129.92 
12 288 125849.44 
13 312 141469.12 
14 336 144108.16 
15 360 176436.48 
16 384 196057.60 
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Fig 13: Daily Drug Release 
 
 
 
Table 2 shows the Fluorescence intensity studies taken every 24th hour for a period of 16 
days. The plotted graph for table 2 shows the drug release profile. The Fluorescence intensity 
increased from 8107.21 on day 1 to 196057.60 day 16. 
Increase in fluorescence intensities supports the prolonged release of the drug at a 
predetermined rate by maintaining a constant drug level at a specified period of time. The 
sustained release studies observed up to 16 days which shows more bioavailability of drug for 
long time. Combination of different liposomes and inverted micelle can give a much prolonged 
drug release which has to be further investigated. 
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CONCLUSION 
 
 “Nanoparticulate drug delivery system for vitreous humor” has the ability to provide 
the drug delivery into the eye. Preparation of antibiotics in a nanoparticulate form can be used to 
prevent infections in treatment of cataract surgery and age related macula. Nanoparticulated drug 
delivery shows lesser side effects when compared to antibiotics prepared for oral administration 
and for instillation into the eye. The antibiotic drug prepared in nanoparticulate form can be 
directly applied to the location of surgery which reduces the first pass metabolism. Intra ocular 
lens implantation is the main feature of cataract surgery. Fluorescence studies show that the drug 
is completely encapsulated into the prepared liposome nanoparticles. Sustained release study 
results indicated that the prepared nanoparticles provided sustained release of the drug for about 
16 days. Cytotoxicity test are to be performed in order to test the toxicity of the formulation. 
Further research should be carried out by preparing different types of formulations of 
nanoparticles by using different types of drugs. 
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